Np mrd loader

Record Information
Version2.0
Created at2022-09-07 17:13:01 UTC
Updated at2022-09-07 17:13:01 UTC
NP-MRD IDNP0253363
Secondary Accession NumbersNone
Natural Product Identification
Common Nameepirubicin
DescriptionEpirubicin, also known as 4'-epiadriamycin or farmorubicin, belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage. Epirubicin is a drug which is used for use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Epirubicin is a very strong basic compound (based on its pKa). Epirubicin is a potentially toxic compound. epirubicin is found in Streptomyces venezuelae. epirubicin was first documented in 2001 (PMID: 11432615). An anthracycline that is the 4'-epi-isomer of doxorubicin (PMID: 15821120) (PMID: 16005104) (PMID: 17604344) (PMID: 18838875).
Structure
Thumb
Synonyms
ValueSource
4'-EpiadriamycinChEBI
EpiadriamycinChEBI
EpirubicinaChEBI
EpirubicineChEBI
EpirubicinumChEBI
PidorubicinaChEBI
PidorubicineChEBI
PidorubicinumChEBI
FarmorubicinKegg
EllenceHMDB
FarmorubicineHMDB
IMI 28HMDB
IMI28HMDB
Lemery brand OF epirubicin hydrochlorideHMDB
PharmorubicinHMDB
Cell pharm brand OF epirubicinHMDB
4' Epi adriamycinHMDB
4' Epi DXRHMDB
4' EpiadriamycinHMDB
4' EpidoxorubicinHMDB
4'-Epi-adriamycinHMDB
4'-Epi-doxorubicinHMDB
EPIcellHMDB
FarmorubicinaHMDB
4'-EpidoxorubicinHMDB
EPI cellHMDB
Hydrochloride, epirubicinHMDB
IMI-28HMDB
4' Epi doxorubicinHMDB
4'-Epi-DXRHMDB
EPI-cellHMDB
EpilemHMDB
Epirubicin hydrochlorideHMDB
Kenfarma brand OF epirubicin hydrochlorideHMDB
Pfizer brand OF epirubicin hydrochlorideHMDB
EpirubicinChEBI
Chemical FormulaC27H29NO11
Average Mass543.5193 Da
Monoisotopic Mass543.17406 Da
IUPAC Name(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
Traditional Nameepirubicin
CAS Registry NumberNot Available
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
InChI Identifier
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
InChI KeyAOJJSUZBOXZQNB-VTZDEGQISA-N
Experimental Spectra
Not Available
Predicted Spectra
Spectrum TypeDescriptionDepositor IDDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 25 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 100 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 252 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 1000 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 50 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 200 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 75 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 300 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 101 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 400 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 126 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 151 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 600 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 176 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 700 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 201 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 800 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 226 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 900 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Chemical Shift Submissions
Not Available
Species
Species of Origin
Species NameSourceReference
Streptomyces venezuelaeLOTUS Database
Chemical Taxonomy
Description Belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative Parents
Substituents
  • Anthracycline
  • Anthracyclinone-skeleton
  • Aminoglycoside core
  • Tetracenequinone
  • 9,10-anthraquinone
  • 1,4-anthraquinone
  • Anthracene
  • Hexose monosaccharide
  • Glycosyl compound
  • O-glycosyl compound
  • Tetralin
  • Aryl ketone
  • Anisole
  • Amino saccharide
  • Alkyl aryl ether
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Vinylogous acid
  • Tertiary alcohol
  • Alpha-hydroxy ketone
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Ketone
  • Acetal
  • Organoheterocyclic compound
  • Polyol
  • Ether
  • Oxacycle
  • Alcohol
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Organooxygen compound
  • Organic nitrogen compound
  • Amine
  • Primary amine
  • Primary alcohol
  • Primary aliphatic amine
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP1.41ALOGPS
logP0.92ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)9.53ChemAxon
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area206.07 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity134.59 m³·mol⁻¹ChemAxon
Polarizability53.88 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDHMDB0014588
DrugBank IDDB00445
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID38201
KEGG Compound IDC11230
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkEpirubicin
METLIN IDNot Available
PubChem Compound41867
PDB IDNot Available
ChEBI ID47898
Good Scents IDNot Available
References
General References
  1. Razis ED, Fountzilas G: Paclitaxel: epirubicin in metastatic breast cancer--a review. Ann Oncol. 2001 May;12(5):593-8. doi: 10.1023/a:1011108807105. [PubMed:11432615 ]
  2. Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS, Doval DC, Ermisch S, Roychowdhury D, Miller MA, von Minckwitz G: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005 Jun;16(6):899-908. doi: 10.1093/annonc/mdi181. Epub 2005 Apr 8. [PubMed:15821120 ]
  3. Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, Lecomte J, Collon T, Mommen P, Sculier JP: A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 2005 Oct;50(1):75-82. doi: 10.1016/j.lungcan.2005.05.007. [PubMed:16005104 ]
  4. Iwakiri T, Okumura M, Hidaka M, Kumagai Y, Ichihara E, Kawano Y, Arimori K: Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes. J Appl Toxicol. 2008 Apr;28(3):329-36. doi: 10.1002/jat.1283. [PubMed:17604344 ]
  5. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD: A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol. 2008 Oct;31(5):413-6. doi: 10.1097/COC.0b013e318168ef2a. [PubMed:18838875 ]
  6. LOTUS database [Link]